Jillia Schlingman is a journalist for Dark Daily, specializing in healthcare and medical laboratory news. With a focus on providing timely and informative articles, Jillia covers a wide range of topics including healthcare technology, research studies, and industry trends. Her work aims to keep readers updated on the latest developments in the healthcare field.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Jillia Schlingman's coverage is primarily focused on healthcare and medical research, with an emphasis on data-driven reporting and press releases. Her articles often cite data and cover a range of topics within the healthcare sector such as medical research, genetics, technology in healthcare, workforce shortages, and specific studies or guidelines from reputable institutions.
Given her preference for citing data and covering a variety of themes within the healthcare industry, she would likely be interested in pitches that offer access to new research findings or insights backed by robust data. Moreover, given her focus on workforce shortage issues in healthcare along with technological advancements, offering expert commentary on these areas could also be well-received.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Jillia Schlingman
Use of artificial intelligence in clinical laboratory testing could improve the diagnosis of cancer worldwide
By: Jillia Schlingman
Researchers used CRISPR-based assays to develop new clinical laboratory point-of-care blood test which boasts accuracy, affordability, and accessibility
By: Jillia Schlingman
.American Cancer Society and WHO report on growing global ‘cancer burden’ with cases increasing 77% by 2050.
By: Jillia Schlingman
Further research could eventually lead to clinical laboratory biomarkers and screening tests to identify infants whose gut bacteria may predispose them to neurodevelopment disorders later in life
By: Jillia Schlingman
Findings could lead to new biomarkers for targeted therapies and clinical laboratory tests for multiple diseases
By: Jillia Schlingman
As new diagnostic assays are cleared by regulators, clinical laboratories will play a key role in identifying appropriate patients for new less-invasive Alzheimer's tests
By: Jillia Schlingman
Are “on-demand” leaders the answer to clinical laboratory and pathology group staff shortages? Perhaps. A new twist on management philosophies is gaining steam in hospitals: Hiring on-demand managers and executives to fill gaps in high-level staff. The practice is growing quickly and making its mark.
By: Jillia Schlingman
Findings may lead to new clinical laboratory biomarkers for predicting risk of developing MS and other autoimmune diseases
By: Jillia Schlingman
Scientists suspect that the plastics can be linked to a host of medical conditions, but clear evidence is elusive without appropriate biomarkers for clinical laboratory testing
By: Jillia Schlingman
Request for money upfront comes at a time when many patients already struggle with medical debt
(833) 317-6278 